{rfName}
Ne

Indexed in

License and use

Citations

22

Altmetrics

Analysis of institutional authors

Ruiz De Porras VAuthorPardo JcAuthorEtxaniz OAuthorFont ACorresponding Author

Share

October 20, 2022
Publications
>
Review
No

Neoadjuvant therapy for muscle-invasive bladder cancer: Current clinical scenario, future perspectives, and unsolved questions

Publicated to:Critical Reviews In Oncology Hematology. 178 103795- - 2022-10-01 178(), DOI: 10.1016/j.critrevonc.2022.103795

Authors: Porras, VRD; Pardo, JC; Etxaniz, O; Font, A

Affiliations

Catalan Inst Oncol, Badalona Appl Res Grp Oncol B ARGO, Badalona 08916, Spain - Author
Catalan Inst Oncol, Med Oncol Dept, Ctra Can Ruti Cami Escoles S-N, Badalona 08916, Spain - Author
Catalan Institute of Oncology, Badalona Applied Research Group in Oncology (B·ARGO), Badalona, 08916, Spain, Germans Trias i Pujol Research Institute (IGTP), Badalona, 08916, Spain - Author
Catalan Institute of Oncology, Badalona Applied Research Group in Oncology (B·ARGO), Badalona, 08916, Spain, Germans Trias i Pujol Research Institute (IGTP), Badalona, 08916, Spain, Medical Oncology Department, Catalan Institute of Oncology, Ctra. Can Rut - Author
Germans Trias & Pujol Res Inst IGTP, Badalona 08916, Spain - Author
See more

Abstract

Keywords

cisplatindose-dense methotrexatedoxorubicinimmunotherapyneoadjuvant therapyoutcomesperioperative chemotherapyphase-iii trialpredictive biomarkerradical cystectomysurvivalurothelial carcinomavinblastineAdjuvant chemotherapyAgingAtezolizumabBempegaldesleukinBladder preservationBladder tumorCancer classificationCancer immunotherapyCancer prognosisCancer riskCancer stagingCancer survivalCarboplatinChemotherapy, adjuvantCirculating tumor dnaCisplatinCisplatin-based chemotherapyClinical practiceCystectomyDna repairDrug safetyDurvalumabEnfortumab vedotinGemcitabineHistologyHumanHumansImmunotherapyIpilimumabLinrodostatMuscleMuscle invasive bladder cancerMuscle-invasive bladder cancerMusclesNeoadjuvant chemotherapyNeoadjuvant therapyNeoplasm invasivenessNivolumabOrgan preservationPathologyPembrolizumabPersonalized medicinePredictive biomarkerPredictive valueReviewSex differenceSmokingTicilimumabTreatment responseTumor invasionUrinary bladder neoplasms

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Critical Reviews In Oncology Hematology due to its progression and the good impact it has achieved in recent years, according to the agency WoS (JCR), it has become a reference in its field. In the year of publication of the work, 2022, it was in position 54/241, thus managing to position itself as a Q1 (Primer Cuartil), in the category Oncology.

From a relative perspective, and based on the normalized impact indicator calculated from World Citations from Scopus Elsevier, it yields a value for the Field-Weighted Citation Impact from the Scopus agency: 1.06, which indicates that, compared to works in the same discipline and in the same year of publication, it ranks as a work cited above average. (source consulted: ESI Nov 14, 2024)

This information is reinforced by other indicators of the same type, which, although dynamic over time and dependent on the set of average global citations at the time of their calculation, consistently position the work at some point among the top 50% most cited in its field:

  • Field Citation Ratio (FCR) from Dimensions: 5.11 (source consulted: Dimensions Jul 2025)

Specifically, and according to different indexing agencies, this work has accumulated citations as of 2025-07-08, the following number of citations:

  • WoS: 8
  • Scopus: 10

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-07-08:

  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 12 (PlumX).

Leadership analysis of institutional authors

There is a significant leadership presence as some of the institution’s authors appear as the first or last signer, detailed as follows: First Author (RUIZ DE PORRAS FONDEVILLA, VICENTE) and Last Author (Font Pous, Albert).

the author responsible for correspondence tasks has been Font Pous, Albert.